Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Saved in:
| Title: | Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. |
|---|---|
| Authors: | Al-Batran SE; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany. Electronic address: albatran.salah@khnw.de., Hofheinz RD; Medical Department III, Universitätsmedizin Mannheim, Mannheim, Germany., Pauligk C; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany., Kopp HG; Medical Department II, University Hospital, Tübingen, Germany., Haag GM; National Center for Tumor Diseases, University Hospital Heidelberg, Medical Oncology, Heidelberg, Germany., Luley KB; Universitätsklinikum Schleswig-Holstein, Medical Department I Hematology/Oncology, Lübeck, Germany., Meiler J; West German Cancer Center, Department of Medical Oncology, and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany., Homann N; Klinikum Wolfsburg, Medical Department II, Wolfsburg, Germany., Lorenzen S; Klinikum rechts der Isar der TU München, Medical Department III, Munich, Germany., Schmalenberg H; Department of Internal Medicine II, University Hospital Jena, Germany., Probst S; Klinikum Bielefeld, Department for Hematology and Oncology, Bielefeld, Germany., Koenigsmann M; MediProjekt, Gesellschaft für Medizinstatistik und Projektentwicklung, Hannover, Germany., Egger M; Ortenau Klinikum Lahr, Medical Department, Lahr, Germany., Prasnikar N; Klinikum Ludwigsburg, Medical Department I, Ludwigsburg, Germany., Caca K; Klinikum Ludwigsburg, Medical Department I, Ludwigsburg, Germany., Trojan J; Medical Department I, Goethe University Medical Center, Frankfurt, Germany., Martens UM; SLK-Kliniken, Medical Department III, Cancer Center Heilbronn-Franken, Heilbronn, Germany., Block A; University Hospital Hamburg-Eppendorf, Department for Oncology and Hematology, Hamburg, Germany., Fischbach W; Klinikum Aschaffenburg, Medical Department II, Aschaffenburg, Germany., Mahlberg R; Klinikum Mutterhaus der Borromäerinnen, Medical Department I, Trier, Germany., Clemens M; Klinikum Mutterhaus der Borromäerinnen, Medical Department I, Trier, Germany., Illerhaus G; Universitätsklinikum Freiburg, Medical Department I, Freiburg, Germany., Zirlik K; Universitätsklinikum Freiburg, Medical Department I, Freiburg, Germany., Behringer DM; Augusta-Krankenanstalt, Department for Hematology, Oncology and Palliative Medicine, Bochum, Germany., Schmiegel W; Department of Internal Medicine, Ruhr-University Bochum, Bochum, Germany., Pohl M; Department of Internal Medicine, Ruhr-University Bochum, Bochum, Germany., Heike M; Klinikum Dortmund, Medical Department, Dortmund, Germany., Ronellenfitsch U; Department of Surgery, Universitätsmedizin Mannheim, Mannheim, Germany., Schuler M; West German Cancer Center, Department of Medical Oncology, and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany., Bechstein WO; Department of General and Visceral Surgery, Goethe University Medical Center, Frankfurt, Germany., Königsrainer A; Department of Surgery and Transplantation, University Hospital, Tübingen, Germany., Gaiser T; Department of Pathology, Universitätsmedizin Mannheim, Mannheim, Germany., Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Medical Oncology, Heidelberg, Germany., Hozaeel W; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany., Reichart A; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany., Goetze TO; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany., Sievert M; Sanofi Genzymy, Berlin, Germany., Jäger E; Department of Hematology-Oncology, Krankenhaus Nordwest, Frankfurt, Germany., Mönig S; Hôpitaux Universitaires de Genève, Service de Chirurgie Viscérale, Geneva, Switzerland., Tannapfel A; Institute for Pathology, Ruhr-University Bochum, Bochum, Germany. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2016 Dec; Vol. 17 (12), pp. 1697-1708. Date of Electronic Publication: 2016 Oct 22. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
